Yamin ‘Mo’ Khan, Open Orphan's CEO, talks about a new £7.2mln contract for an RSV anti-viral vaccine challenge trial.
RSV impacts every baby under the age of two he says, with, in rare cases, it being a life-threatening disease.
It affects the elderly as well and this contract, with an existing 'top five' pharma customer, will target an area of clear unmet need.